Prothena Past Earnings Performance

Past criteria checks 0/6

Prothena has been growing earnings at an average annual rate of 3%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 45.8% per year.

Key information

3.0%

Earnings growth rate

9.7%

EPS growth rate

Biotechs Industry Growth11.5%
Revenue growth rate45.8%
Return on equity-26.2%
Net Margin-160.9%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Prothena makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0Y3M Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2391-147620
30 Sep 23141-73580
30 Jun 2358-141530
31 Mar 2355-128520
31 Dec 2254-117500
30 Sep 225-156490
30 Jun 22143-1490
31 Mar 2220267470
31 Dec 2120167460
30 Sep 2120069440
30 Jun 2161-70410
31 Mar 211-124400
31 Dec 201-111390
30 Sep 201-102370
30 Jun 201-91360
31 Mar 201-80360
31 Dec 191-78360
30 Sep 191-79360
30 Jun 191-84360
31 Mar 191-128380
31 Dec 181-156420
30 Sep 181-181490
30 Jun 181-209520
31 Mar 1827-167520
31 Dec 1728-153480
30 Sep 1727-154350
30 Jun 1728-145390
31 Mar 171-168360
31 Dec 161-160320
30 Sep 161-135380
30 Jun 161-115280
31 Mar 161-93250
31 Dec 152-81230
30 Sep 153-70210
30 Jun 154-60200
31 Mar 1519-40190
31 Dec 1451-7190
30 Sep 1449-5190
30 Jun 1448-2180
31 Mar 1433-14170
31 Dec 131-41150
30 Sep 131-42130
30 Jun 132-41110
31 Mar 132-40110

Quality Earnings: 0Y3M is currently unprofitable.

Growing Profit Margin: 0Y3M is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0Y3M is unprofitable, but has reduced losses over the past 5 years at a rate of 3% per year.

Accelerating Growth: Unable to compare 0Y3M's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0Y3M is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.2%).


Return on Equity

High ROE: 0Y3M has a negative Return on Equity (-26.19%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.